Low plasma adiponectin levels and risk of colorectal cancer in men: A prospective study

Journal of the National Cancer Institute

Volumn 97, Issue 22, 2005, Pages 1688-1694

  Wei, Esther K ^a,b   Giovannucci, Edward ^a,b   Fuchs, Charles S ^a,c   Willett, Walter C ^a,b   Mantzoros, Christos S ^d  

^a HARVARD MEDICAL SCHOOL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADIPONECTIN; ALPHA TOCOPHEROL; CALCIUM; FOLIC ACID; VITAMIN D;

ADULT; AGED; ALCOHOLISM; ARTICLE; BLOOD SAMPLING; BODY MASS; CALCIUM INTAKE; CANCER INCIDENCE; CANCER RISK; CIGARETTE SMOKING; COLON CARCINOGENESIS; COLORECTAL CANCER; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIETARY INTAKE; DRUG USE; FAMILY HISTORY; FOLLOW UP; HORMONE BLOOD LEVEL; HUMAN; LIFESTYLE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUESTIONNAIRE; RISK ASSESSMENT; RISK REDUCTION; STATISTICAL ANALYSIS; VITAMIN SUPPLEMENTATION;

ADIPONECTIN; ADULT; AGED; BODY MASS INDEX; CASE-CONTROL STUDIES; COLORECTAL NEOPLASMS; CONFOUNDING FACTORS (EPIDEMIOLOGY); FEMALE; HUMANS; INSULIN RESISTANCE; LOGISTIC MODELS; MALE; MIDDLE AGED; OBESITY; ODDS RATIO; PROSPECTIVE STUDIES; RESEARCH DESIGN; RISK ASSESSMENT; RISK FACTORS;

EID: 27944506001     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/dji376     Document Type: Article

References (41)

1. Giovannucci E. Insulin, insulin-like growth factors and colon cancer: A review of the evidence. J Nutr 2001;131(11 Suppl):3109S-20S.
2. Hu FB, Manson JE, Liu S, Hunter D, Colditz GA, Michels KB, et al. Prospective study of adult onset diabetes mellitus (type 2) and risk of colorectal cancer in women. J Natl Cancer Inst 1999;91;542-7.
3. Giovannucci E, Ascherio A, Rimm EB, Colditz GA, Stampfer MJ, Willett WC. Physical activity, obesity, and risk for colon cancer and adenoma in men. Ann Intern Med 1995;122:327-34.
4. Caan BJ, Coates AO, Slattery ML, Potter JD, Quesenberry CP Jr, Edwards SM. Body size and the risk of colon cancer in a large case-control study. Int J Obes Relat Metab Disord 1998;22:178-84.
5. Carey VJ, Walters EE, Colditz GA, Solomon CG, Willett WC, Rosner BA, et al. Body fat distribution and risk of non-insulin-dependent diabetes mellitus in women. The Nurses' Health Study. Am J Epidemiol 1997;145:614-9.
6. Martinez ME, Giovannucci E, Spiegelman D, Hunter DJ, Willett WC, Colditz GA. Leisure-time physical activity, body size, and colon cancer in women. Nurses' Health Study Research Group. J Natl Cancer Inst 1997;89:948-55.
7. Sandhu MS, Dunger DB, Giovannucci EL. Insulin, insulin-like growth factor-I (IGF-I), IGF binding proteins, their biologic interactions, and colorectal cancer. J Natl Cancer Inst 2002;94:972-80.
8. Ma J, Giovannucci E, Pollak M, Leavitt A, Tao Y, Gaziano JM, et al. A prospective study of plasma C-peptide and colorectal cancer risk in men. J Natl Cancer Inst 2004;96:546-53.
9. Giovannucci E, Pollak MN, Platz EA, Willett WC, Stampfer MJ, Majeed N, et al. A prospective study of plasma insulin-like growth factor-I and binding protein-3 and risk of colorectal neoplasia in women. Cancer Epidemiol Biomarkers Prev 2000;9:345-9.
10. Wei EK, Ma J, Pollak MN, Rifai N, Fuchs CS, Hankinson SE, et al. A prospective study of C-peptide, insulin-like growth factor-I, insulin-like growth factor binding protein-1, and the risk of colorectal cancer in women. Cancer Epidemiol Biomarkers Prev 2005;14:850-5.
11. Tschritter O, Fritsche A, Thamer C, Haap M, Shirkavand F, Rahe S, et al. Plasma adiponectin concentrations predict insulin sensitivity of both glucose and lipid metabolism. Diabetes 2003;52:239-43.
12. Diez JJ, Iglesias P. The role of the novel adipocyte-derived hormone adiponectin in human disease. Eur J Endocrinol 2003;148:293-300.
13. Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF. A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 1995;270:26746-9.
14. Cnop M, Havel PJ, Utzschneider KM, Carr DB, Sinha MK, Boyko EJ, et al. Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: Evidence for independent roles of age and sex. Diabetologia 2003;46:459-69.
15. Trujillo ME, Scherer PE. Adiponectin - journey from an adipocyte secretory protein to biomarker of the metabolic syndrome. J Intern Med 2005;257:167-75.
16. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999;257:79-83.
17. Shetty GK, Economides PA, Horton ES, Mantzoros CS, Veves A. Circulating adiponectin and resistin levels in relation to metabolic factors, inflammatory markers, and vascular reactivity in diabetic patients and subjects at risk for diabetes. Diabetes Care 2004;27:2450-7.
18. Rimm EB, Stampfer MJ, Colditz GA, Chute CG, Litin LB, Willett WC. Validity of self-reported waist and hip circumferences in men and women. Epidemiology 1990;1:466-73.
19. Chasan-Taber L, Erickson JB, Nasca PC, Chasan-Taber S, Freedson PS. Validity and reproducibility of a physical activity questionnaire in women. Med Sci Sports Exerc 2002;34:987-92.
20. Rimm EB, Giovannucci EL, Stampfer MJ, Colditz GA, Litin LB, Willett WC. Reproducibility and validity of an expanded self-administered semiquantitative food frequency questionnaire among male health professionals. Am J Epidemiol 1992;135:1114-26; discussion 1127-36.
21. Willett WC, Sampson L, Stampfer MJ, Rosner B, Bain C, Witschi J, et al. Reproducibility and validity of a semiquantitative food frequency questionnaire. Am J Epidemiol 1985;122:51-65.
22. Pischon T, Hotamisligil GS, Rimm EB. Adiponectin: Stability in plasma over 36 hours and within-person variation over-1 year. Clin Chem 2003; 49:650-2.
23. Rosner B. Percentage points for generalized ESD many-outlier procedure. Technometrics 1983;25:165-72.
24. Skibber JM, Minsky BD, Hoff PM. Cancer of the Colon. In: DeVita VT, Hellman S, Rosenberg SA, editors. Cancer: Principles & practice of oncology. 6th ed. Philadelphia (PA): Lippincott, William and Wilkins; 2001. p. 1230-1.
25. Pollak MN, Schernhammer ES, Hankinson SE. Insulin-like growth factors and neoplasia. Nat Rev Cancer 2004;4:505-18.
26. Moschos SJ, Mantzoros CS. The role of the IGF system in cancer: From basic to clinical studies and clinical applications. Oncology 2002;63:317-32.
27. Ma J, Pollak M, Giovannucci E, Chan JM, Tho Y, Hennekens C, et al. A prospective study of plasma levels of insulin-like growth factor I (IGF-I) and IGF-binding protein-3, and colorectal cancer risk among men. Growth Horm IGF Res 2000;10 Suppl A:S28-9.
28. Manousos O, Souglakos J, Bosetti C, Tzonou A, Chatzidakis V, Trichopoulos D, et al. IGF-I and IGF-II in relation to colorectal cancer. Int J Cancer 1999;83:15-7.
29. Petridou E, Mantzoros C, Dessypris N, Koukoulomatis P, Addy C, Voulgaris Z, et al. Plasma adiponectin concentrations in relation to endometrial cancer: A case-control study in Greece. J Clin Endocrinol Metab 2003;88:993-7.
30. Dal Maso L, Augustin LS, Karalis A, Talamini R, Franceschi S, Trichopoulos D, et al. Circulating adiponectin and endometrial cancer risk. J Clin Endocrinol Metab 2004;89:1160-3.
31. Mantzoros C, Petridou E, Dessypris N, Chavelas C, Dalamaga M, Alexe DM, et al. Adiponectin and breast cancer risk. J Clin Endocrinol Metab 2004;89:1102-7.
32. Ishikawa M, Kitayama J, Kazama S, Hiramatsu T, Hatano K, Nagawa H. Plasma adiponectin and gastric cancer. Clin Cancer Res 2005;11(2 Pt 1): 466-72.
33. Pajvani UB, Du X, Combs TP, Berg AH, Rajala MW, Schulthess T, et al. Structure-function studies of the adipocyte-secreted hormone Acrp30/ adiponectin. Implications for metabolic regulation and bioactivity. J Biol Chem 2003;278:9073-85.
34. Pajvani UB, Hawkins M, Combs TP, Rajala MW, Doebber T, Berger JP, et al. Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. J Biol Chem 2004;279:12152-62.
35. Maeda N, Shimomura I, Kishida K, Nishizawa H, Matsuda M, Nagaretani H, et al. Diet-induced insulin resistance in mice lacking adiponectin/ ACRP30. Nat Med 2002;8:731-7.
36. Kubota N, Terauchi Y, Yamauchi T, Kubota T, Moroi M, Matsui J, et al. Disruption of adiponectin causes insulin resistance and neointimal formation. J Biol Chem 2002;277:25863-6.
37. Luo Z, Saha AK, Xiang X, Ruderman NB. AMPK, the metabolic syndrome and cancer. Trends Pharmacol Sci 2005;26:69-76.
38. Thamer C, Haap M, Bachmann O, Zur Nieden T, Tschritter O, Stefan N, et al. Serum adiponectin levels predict the effect of short-term dietary interventions on insulin sensitivity in humans. Diabetologia 2004;47: 1303-5.
39. Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 2004;291:1730-7.
40. Brakenhielm E, Veitonmaki N, Cao R, Kihara S, Matsuzawa Y, Zhivotovsky B, et al. Adiponectin-induced antiangiogenesis and antitumor activity involve caspase-mediated endothelial cell apoptosis. Proc Natl Acad Sci U S A 2004; 101:2476-81.
41. Yokota T, Oritani K, Takahashi I, Ishikawa J, Matsuyama A, Ouchi N, et al. Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood 2000;96:1723-32.